Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blue Jet HealthcareBOM:544009 +1.05%65 Return-on-Tangible-Equity is 23.06% as of Jun. 2026, which is 20% below its 10-year median of 28.74. GuruFocus rates BOM:544009 with a GF Score™ of 65/100 and a GF Value™ of ₹515.12 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 1,201 Biotechnology companies, Blue Jet Healthcare ranks better than 90.59% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Blue Jet Healthcare's annualized net income for the quarter that ended in Jun. 2026 was ₹3,131 Mil. Blue Jet Healthcare's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹13,577 Mil. Therefore, Blue Jet Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 23.06%.
The historical rank and industry rank for Blue Jet Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544009'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.82 Med: 28.74 Max: 42.16
Current: 18.82
During the past 6 years, Blue Jet Healthcare's highest Return-on-Tangible-Equity was 42.16%. The lowest was 18.82%. And the median was 28.74%.
BOM:544009's Return-on-Tangible-Equity is ranked better than 90.59% of 1201
companies
in the Biotechnology industry
Industry Median: -42.68
vs BOM:544009: 18.82
Blue Jet Healthcare (BOM:544009) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Blue Jet Healthcare Return-on-Tangible-Equity Related Terms
Blue Jet Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blue Jet Healthcare Return-on-Tangible-Equity Chart
BOM:544009 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 23.06% mean?
Blue Jet Healthcare (BOM:544009) has a Return-on-Tangible-Equity of 23.06% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Blue Jet Healthcare and its competitors. This is 20% below median its historical median of 28.74. Over the past decade, Blue Jet Healthcare's Return-on-Tangible-Equity has ranged from 18.82 to 42.16. According to the industry distribution chart, Blue Jet Healthcare ranks #113 out of 1201 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Blue Jet Healthcare's Return-on-Tangible-Equity too high?
Blue Jet Healthcare's current Return-on-Tangible-Equity of 23.06% is 20% below median its 10-year median of 28.74. Over the past 10 years, this metric has ranged from a low of 18.82 to a high of 42.16. Based on the distribution chart, Blue Jet Healthcare ranks #113 out of 1201 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Blue Jet Healthcare has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #113 out of 1201 companies for Return-on-Tangible-Equity. This places Blue Jet Healthcare in the top 9% of its industry — outperforming the majority of peers. Historically, Blue Jet Healthcare's own Return-on-Tangible-Equity has ranged from 18.82 to 42.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Blue Jet Healthcare and its competitors. Blue Jet Healthcare's current Return-on-Tangible-Equity is 23.06%, which is 20% below median its own 10-year median of 28.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹515.12, compared to a current price of ₹593.80 — trading 15.3% above its estimated fair value. The current Return-on-Tangible-Equity is 23.06%, which is 20% below median its 10-year median of 28.74. Blue Jet Healthcare's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current Return-on-Tangible-Equity is 23.06% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹593.80 is trading 15.3% above its estimated GF Value™ of ₹515.12.
GuruFocus considers Blue Jet Healthcare to be Modestly Overvalued.
Key valuation signals for BOM:544009:
Return-on-Tangible-Equity: 23.06% (20% below median its 10-year median of 28.74)
GF Value™: ₹515.12 vs. price of ₹593.80 (15.3% above fair value)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
65GF Score
Get the complete analysis for BOM:544009
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
